The term “advanced adenoma” carries an ominous connotation, as it signifies a high risk for colorectal cancer (CRC), causing concern for both patients and clinicians. Evidence, including data from the New Hampshire Colonoscopy Registry, supports this concern by showing that individuals with advanced adenomas face a higher risk of future advanced neoplasia—defined as the combined risk of CRC and other advanced adenomas—compared to those with non-advanced or no polyps.
Post-ERCP pancreatitis is the most common adverse event following biliary drainage with ERCP and may delay oncologic therapy. Strategies that reduce this risk without compromising efficacy are clinically important. In addition, there has been emerging data on EUS-CDS as a primary modality in treatment of malignant distal biliary obstruction.
This study moves beyond diagnostic accuracy to evaluate real-world clinical impact. By randomizing primary care teams and embedding AI-ECG alerts directly into clinician workflows — without additional patient contact — the trial tests a pragmatic “screen-to-diagnosis” pathway. The observed and two-fold increase in detection of advanced CLD in the overall cohort, and more than four-fold increase among AI-ECG–positive patients, demonstrate that AI-enabled screening can shift detection upstream to a clinically actionable stage, where interventions to prevent decompensation and remain possible.
Rigid adherence to performance targets—particularly for cannulation success or prophylactic pancreatic stent placement—may inadvertently encourage overly aggressive maneuvers that increase procedural risk. These indicators are intended for internal quality improvement and benchmarking, not for credentialing, reimbursement, or punitive comparison.
EUS-Guided Versus Surgical Gastroenterostomy: Which Endures? (The ENDURO trial) Margaret J. Zhou, MD Clinical Assistant Professor of Medicine, Gastroenterology &…
In this single-center pilot study, FMT was safe and well tolerated, with no related serious adverse events and early signals of reduced bloodstream infections and antibiotic use among LTACH patients colonized with MDROs.
This updated 2025 guideline addresses critical topics including prevention of mother-to-child transmission and horizontal transmission, treatment in immune-tolerant and indeterminate phases (“grey zone”), treatment discontinuation, and hepatocellular carcinoma (HCC) surveillance.
The guidelines still emphasize the importance of preconception counseling and achieving disease remission prior to conception to lower the risk of adverse pregnancy outcomes. Decreased fertility remains an important outcome in post-surgical patients, especially in patients with ileal pouch anal anastomosis.
Many gastroenterologists encounter patients with subtle tongues of salmon-colored mucosa or an irregular Z-line that is biopsied, but guidelines disagree on whether segments <1 cm should be labeled as BE or followed at all. Some societies exclude USBE due to measurement variability and presumed minimal cancer risk. This study provides long-term outcome data to help clinicians understand whether USBE is clinically meaningful, challenging the assumption that these short segments are benign and transient.
With presumed standard-of-care prophylactic colectomies and surveillance colonoscopies (in the United States), most FAP patients will fortunately not develop cancer, although the risk overall is still markedly higher than the average-risk patient without FAP.
